William Engelman

Associate Director, Patient Safety and Risk Management at Alnylam Pharmaceuticals - Cambridge, Massachusetts, US

William Engelman's Colleagues at Alnylam Pharmaceuticals
Xun Zhou

Director, R&D Informatics / IT

Contact Xun Zhou

Eric McKinney

Senior Director, CMC Regulatory Affairs

Contact Eric McKinney

Randy Miller

US Medical Director (2019-Present); National MSL Director (2017-Present)

Contact Randy Miller

David Erbe

Senior Distinguished Investigator

Contact David Erbe

Elena Yureneva

Sr Director, Global Patient Safety & Risk Mgmnt

Contact Elena Yureneva

Krista Satterly

Senior Manager, Internal Communications

Contact Krista Satterly

View All William Engelman's Colleagues
William Engelman's Contact Details
HQ
(617) 551-8200
Location
Cambridge, Massachusetts, United States
Company
Alnylam Pharmaceuticals
William Engelman's Company Details
Alnylam Pharmaceuticals logo, Alnylam Pharmaceuticals contact details

Alnylam Pharmaceuticals

Cambridge, Massachusetts, US • 2460 Employees
SaaS

ALNYLAM IS LEADING THE RNAi REVOLUTION™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, four more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,500+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-23), Science Magazine (2018-23), Fast Company (Best Workplaces for Innovators 2020-23) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email medinfo@alnylam.com or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861

Rna Therapeutics Innovative Treatments Ocular Disease Treatment
Details about Alnylam Pharmaceuticals
Frequently Asked Questions about William Engelman
William Engelman currently works for Alnylam Pharmaceuticals.
William Engelman's role at Alnylam Pharmaceuticals is Associate Director, Patient Safety and Risk Management.
William Engelman's email address is ***@alnylam.com. To view William Engelman's full email address, please signup to ConnectPlex.
William Engelman works in the SaaS industry.
William Engelman's colleagues at Alnylam Pharmaceuticals are Hollis Lin, Xun Zhou, Eric McKinney, Randy Miller, David Erbe, Elena Yureneva, Krista Satterly and others.
William Engelman's phone number is (617) 551-8200
See more information about William Engelman